In a filing, Apellis Pharmaceuticals Inc revealed its Chief Business & Strat Officer DeLong Mark Jeffrey unloaded Company’s shares for reported $10360.0 on Feb 11 ’25. In the deal valued at $28.54 per share,363 shares were sold. As a result of this transaction, DeLong Mark Jeffrey now holds 83,945 shares worth roughly $2.26 million.
Then, DeLong Mark Jeffrey bought 363 shares, generating $10,360 in total proceeds.
Before that, Watson David O. sold 695 shares. Apellis Pharmaceuticals Inc shares valued at $20,519 were divested by the General Counsel at a price of $29.52 per share. As a result of the transaction, Watson David O. now holds 144,299 shares, worth roughly $3.88 million.
Goldman downgraded its Apellis Pharmaceuticals Inc [APLS] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in late November with a ‘”an Equal-weight”‘ rating. RBC Capital Mkts began covering APLS with “Sector perform” recommendation on October 25, 2024. William Blair started covering the stock on October 16, 2024. It rated APLS as “an Outperform”.
Price Performance Review of APLS
On Tuesday, Apellis Pharmaceuticals Inc [NASDAQ:APLS] saw its stock fall -1.86% to $26.90. Over the last five days, the stock has lost -4.54%. Apellis Pharmaceuticals Inc shares have fallen nearly -15.70% since the year began. Nevertheless, the stocks have fallen -60.20% over the past one year. While a 52-week high of $71.90 was reached on 01/07/25, a 52-week low of $24.34 was recorded on 02/25/25. SMA at 50 days reached $30.59, while 200 days put it at $34.19.
Levels Of Support And Resistance For APLS Stock
The 24-hour chart illustrates a support level at 26.41, which if violated will result in even more drops to 25.93. On the upside, there is a resistance level at 27.53. A further resistance level may holdings at 28.17. The Relative Strength Index (RSI) on the 14-day chart is 35.92, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.10, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 91.58%. Stochastics %K at 13.89% indicates the stock is a buying.
The most recent change occurred on October 16, 2024 when Scotiabank began covering the stock and recommended ‘”a Sector outperform”‘ rating .
